Cell-dependent antithrombotic effect of tranexamic acid.

Background: Tranexamic acid (TXA) is a synthetic lysine analog that inhibits fibrinolysis by blocking lysine-binding sites on plasminogen and plasmin. Although early therapeutic TXA reduces bleeding mortality in major trials, prophylactic benefit appears context- and timing-dependent. TXA is generally not associated with increased thromboembolism, yet its net effect on thrombus formation remains uncertain. Because plasmin(ogen) also acts on leukocytes, endothelium and platelets via cell-surface receptors, TXA may exert cell-dependent effects beyond antifibrinolysis. Objectives: To determine how cellular elements modulate TXA's impact on thrombus formation. Methods: We studied TXA in an Results: TXA reduced the odds of venous thrombus formation by 90% but did not alter thrombus mass once clots formed. VWF: Ag remained unchanged, whereas the stenosis-induced rise in MCP-1 was largely suppressed by TXA. TXA decreased thrombin generation in whole blood but not in platelet-rich plasma, indicating a cellular requirement. Consistently, TXA markedly inhibited leukocyte surface-mediated plasminogen activation within fibrin clots. Tail bleeding was unaffected. Conclusion: TXA was not prothrombotic in venous stasis; it reduced thrombus initiation without impairing primary hemostasis. We show for the first time that TXA modulates thrombin generation in a cellular environment, consistent with inhibition of leukocyte-associated plasmin activity.